Mortes em ensaios clínicos não dissuadem doentes com lúpus que esperam por uma cura

Patients with systemic lupus erythematosus are eager to participate in CAR-T cell therapy trials despite recent deaths in clinical studies. The ongoing trials aim to explore new treatments for this debilitating disease, which often does not respond to current therapies. Doctors report that many patients are willing to take risks for a chance at remission, motivated by success stories. However, recent fatalities have raised concerns about safety, prompting companies like Novartis and Bristol Myers Squibb to suspend some trials. Researchers are investigating the causes of these deaths, with some attributing them to rapid manufacturing processes that may lead to severe inflammatory responses. Despite the risks, many patients remain hopeful for effective treatments.